Clinical Trial Update: Oral Docetaxel (ModraDoc/r) in Combination With Hormonal Treatment and Radiation Therapy in High-risk Prostate Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial of an oral docetaxel formulation (ModraDoc/r) in combination with hormonal therapy and radiation for high-risk prostate cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• ModraDoc/r (docetaxel)

Snippet

Sponsor: The Netherlands Cancer Institute | Conditions: Prostatic Neoplasms | Phase 1 | Status: TERMINATED